首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2013年 1期 => 肝胆胰肿瘤 =>索拉非尼联合塞来昔布对胆管癌细胞..
索拉非尼联合塞来昔布对胆管癌细胞株SK-ChA-1增殖的影响
Effect of sorafenib and celecoxib combination therapy on proliferation of the human cholangiocarcinoma cell line SK-ChA-1 in vitro
文章发布日期:2012年12月14日  来源:  作者:万云燕,李 玲,黄军利,等  点击次数:3352次  下载次数:748次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的研究索拉非尼联合塞来昔布在体外对胆管癌细胞株SK-ChA-1增殖的影响。方法体外培养人胆管癌细胞株SK-ChA-1,通过MTT法检测索拉非尼单用或与塞来昔布联用时对胆管癌细胞株增殖的抑制作用,Western Blot分析索拉非尼单用或与塞来昔布联用时对胆管癌细胞株内多聚ADP核糖聚合酶(PARP)蛋白表达的影响。结果索拉非尼抑制胆管癌细胞株SK-ChA-1的增殖并诱导细胞凋亡。索拉非尼联合塞来昔布协同抑制胆管癌细胞株SK-ChA-1的增殖。塞来昔布使索拉非尼诱导的胆管癌细胞株SK-ChA-1的凋亡增加。结论索拉非尼联合塞来昔布能协同抑制胆管癌细胞株SK-ChA-1的增殖,这与塞来昔布使索拉非尼诱导的细胞凋亡增加有关。
【Abstract】:Abstract:ObjectiveTo investigate the effect of sorafenib and celecoxib combination therapy on proliferation of human cholangiocarcinoma (CC) cells, using the cultured SK-ChA-1 cell line. MethodsInhibition of SK-ChA-1 cell proliferation by sorafenib alone and in combination with celecoxib was studied in vitro using the MTT assay. The anti-neoplastic mechanisms of sorafenib alone and in combination with celecoxib were assessed by Western blot detection of changes in the caspase cleavage substrate poly ADP-ribose polymerase (PARP). ResultsSK-ChA-1 cells treated with sorafenib alone showed a dose-dependent growth inhibition and degradation of PARP. Combination treatment with sorafenib and celecoxib synergistically increased the growth inhibition effects and enhanced the degradation of PARP. ConclusionCombination treatment with sorafenib and celecoxib results in a synergistic anti-proliferative effect in the human CC cell line SK-ChA-1; the addition of celecoxib enhances sorafenib-induced apoptosis.
【关键字】:胆管肿瘤;索拉非尼;塞来昔布;体外研究
【Key words】:bile duct neoplasms; sorafenib; celecoxib; in vitro
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号